TRAF2 is an NF-κB activating oncogene in epithelial cancers

DSpace/Manakin Repository

TRAF2 is an NF-κB activating oncogene in epithelial cancers

Citable link to this page


Title: TRAF2 is an NF-κB activating oncogene in epithelial cancers
Author: Shen, Rhine R.; Zhou, Alicia Y.; Kim, Eejung; O’Connell, Joyce T.; Hagerstrand, Daniel; Beroukhim, Rameen; Hahn, William C.

Note: Order does not necessarily reflect citation order of authors.

Citation: Shen, Rhine R., Alicia Y. Zhou, Eejung Kim, Joyce T. O’Connell, Daniel Hagerstrand, Rameen Beroukhim, and William C. Hahn. 2014. “TRAF2 is an NF-κB activating oncogene in epithelial cancers.” Oncogene 34 (2): 209-216. doi:10.1038/onc.2013.543.
Full Text & Related Files:
Abstract: Aberrant NF-κB activation is frequently observed in human cancers. Genome characterization efforts have identified genetic alterations in multiple components of the NF-κB pathway, some of which have been shown to be essential for cancer initiation and tumor maintenance. Here using patient tumors and cancer cell lines, we identify the NF-κB regulator, TRAF2 as an oncogene that is recurrently amplified and rearranged in 15% of human epithelial cancers. Suppression of TRAF2 in cancer cells harboring TRAF2 copy number gain inhibits proliferation, NF-κB activation, anchorage-independent growth and tumorigenesis. Cancer cells that are dependent on TRAF2 also require NF-κB for survival. The phosphorylation of TRAF2 at serine 11 is essential for the survival of cancer cells harboring TRAF2 amplification. Together these observations identify TRAF2 as a frequently amplified oncogene.
Published Version: doi:10.1038/onc.2013.543
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search